Hasegawa Minoru
Department of Dermatology, Kanazawa University Graduate School of Medical Science.
Nihon Rinsho Meneki Gakkai Kaishi. 2005 Oct;28(5):300-8. doi: 10.2177/jsci.28.300.
Recent studies have revealed that B cells play a critical role in autoimmunity and disease expression through various functions, including autoantibody production, cytokine secretion, antigen presentation, and co-stimulatory effect. Selective targeting of B cells has been recently achieved using a chimeric monoclonal antibody against CD20 (Rituximab). Significant clinical efficacy has been demonstrated in several autoimmune diseases including rheumatoid arthritis and systemic lupus erythematosus by the infusion of this antibody. Rituxumab significantly improves the symptoms during the long period of complete B cell depletion. Understanding the dynamics of B cell involvement in autoimmune diseases will be crucial to the development of B cell-targeted strategies. Conversely, the findings derived from studies of anti-B cell therapy provide us a lot of important clues to clarify the pathogenesis of autoimmune diseases. This review focuses on recent data demonstrating the roles of B cells in autoimmune diseases as well as the current studies concerning the treatment of autoimmune diseases by Rituximab.
最近的研究表明,B细胞通过多种功能在自身免疫和疾病表现中发挥关键作用,这些功能包括自身抗体产生、细胞因子分泌、抗原呈递和共刺激作用。最近,通过使用一种针对CD20的嵌合单克隆抗体(利妥昔单抗)实现了对B细胞的选择性靶向。通过输注这种抗体,已在包括类风湿性关节炎和系统性红斑狼疮在内的几种自身免疫性疾病中证明了显著的临床疗效。在长期完全耗尽B细胞期间,利妥昔单抗可显著改善症状。了解B细胞参与自身免疫性疾病的动态过程对于制定针对B细胞的策略至关重要。相反,抗B细胞治疗研究的结果为阐明自身免疫性疾病的发病机制提供了许多重要线索。本综述重点关注最近证明B细胞在自身免疫性疾病中作用的数据,以及目前关于利妥昔单抗治疗自身免疫性疾病的研究。